ArticleCancer medicine2026
Prediction of Moderate to Severe Delayed Chemotherapy-Induced Nausea Using a Novel Algorithm Incorporating Individual Patient Factors.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeChemotherapy-induced vomiting and nausea (CINV) is difficult to accurately predict, especially in the delayed phase and can negatively affect a patient's' quality of life as well as reduce their motivation to continue lifesaving therapy. We have previously reported on a blood-based assay that can be used to tailor an individualized antiemetic prophylaxis. The purpose of this current study was to validate our previous finding in a larger cohort of patients treated with a platinum-containing regimen.
methodsBlood samples and patient reported outcomes from 202 cancer patients aged 18 years and older who started treatment with a platinum agent during February 15, 2016, through May 18, 2023, were analyzed. The glutathione recycling capacity in red blood cells was compared to reported nausea during the delayed phase and verified by comparison to notes in medical records. An algorithm for risk score prediction was generated and predicted risk scores were compared to observed delayed nausea severity.
resultsPatients with a low glutathione recycling capacity, indicating prolonged exposure to oxidative stress, were experiencing moderate/severe delayed chemotherapy-induced delayed nausea more than those who had an efficient recycling capacity to offset the excess radical oxygen formed by chemotherapy. Calculated risk scores from participating patients demonstrated a good correlation between predicted and observed outcomes for the risk score groups.
conclusionRisk score, based on glutathione recycling and other intrinsic factors, can predict the risk of delayed nausea for patients undergoing chemotherapy, allowing for a more aggressive preventive treatment upfront to avoid or reduce delayed nausea symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.